The judge who oversaw the first punitive damages trial in the Risperdal litigation has decided to slash the award to $6.8 million after a Philadelphia jury handed up a record-busting $8 billion verdict against Janssen Pharmaceuticals last fall.

On Friday, Philadelphia Court of Common Pleas Judge Kenneth Powell granted the post-trial remittitur motion that Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, had filed in the case Murray v. Janssen Pharmaceuticals. According to the docket, Janssen’s post-trial motions were denied in all other respects.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]